Advertisement
Advertisement
RPRX
Royalty Pharma plc Class A Ordinary Shares
50.79
USDSponsored
+0.59
+1.18%
May 08, 15:59 UTC -4
Closed
After-Market
50.52
-0.27
-0.52%
RPRX Earnings Reports
Positive Surprise Ratio
RPRX beat 14 of 24 last estimates.
58%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$658.43M
/$1.28
Implied change from Q1 26 (Revenue/ EPS)
-28.82%
/-1.54%
Implied change from Q2 25 (Revenue/ EPS)
-9.43%
/+13.27%
Royalty Pharma plc Class A Ordinary Shares earnings per share and revenue
On May 06, 2026, RPRX reported earnings of 1.30 USD per share (EPS) for Q1 26, beating the estimate of 1.23 USD, resulting in a 5.11% surprise. Revenue reached 925.00 million, compared to an expected 1.26 billion, with a -26.58% difference. The market reacted with a +0.56% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 1.28 USD, with revenue projected to reach 658.43 million USD, implying an decrease of -1.54% EPS, and decrease of -28.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
FAQ
What were Royalty Pharma plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Royalty Pharma plc Class A Ordinary Shares reported EPS of $1.30, beating estimates by 5.11%, and revenue of $925.00M, -26.58% below expectations.
How did the market react to Royalty Pharma plc Class A Ordinary Shares's Q1 2026 earnings?
The stock price moved up 0.56%, changed from $50.44 before the earnings release to $50.72 the day after.
When is Royalty Pharma plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Royalty Pharma plc Class A Ordinary Shares's next earnings report?
Based on 4
analysts, Royalty Pharma plc Class A Ordinary Shares is expected to report EPS of $1.28 and revenue of $658.43M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement